심부전 치료제 시장 규모, 점유율, 성장률 및 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of heart failure drugs Market

The global heart failure drugs market size was valued at USD 11.79 billion in 2025. The market is projected to grow from USD 13.43 billion in 2026 to USD 38.46 billion by 2034, exhibiting a CAGR of 14.06% during the forecast period from 2026 to 2034. North America dominated the global heart failure drugs market in 2025 with a market share of 43.34%, reaching a valuation of approximately USD 5.11 billion.

The global heart failure drugs market includes prescription therapies used for the management of chronic and acute heart failure conditions across different indications. Market growth is driven by the rising global prevalence of heart failure, aging population, increasing cardiometabolic diseases such as diabetes and hypertension, wider adoption of guideline-directed medical therapy (GDMT), and increasing demand for advanced branded therapies.

The market includes major drug classes such as SGLT2 inhibitors, ARNI, beta blockers, ACE inhibitors & ARBs, mineralocorticoid receptor antagonists, diuretics, and other cardiovascular therapies.

Key players operating in the market include Novartis AG, AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Amgen Inc., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., and Sandoz Inc.

Market Definition and Scope

Heart failure drugs are pharmaceutical products designed to improve heart function, reduce hospitalization risk, control symptoms, and decrease cardiovascular mortality among patients suffering from heart failure.

These medications are used across various heart failure categories, including:

• Heart Failure with Reduced Ejection Fraction (HFrEF)
• Heart Failure with Preserved Ejection Fraction (HFpEF)
• Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)
• Acute Decompensated Heart Failure
• Post-Myocardial Infarction Heart Failure

The market covers branded and generic drugs distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other healthcare channels.

Market Dynamics

Market Trends

Rapid Adoption of SGLT2 Inhibitors Transforming Heart Failure Treatment

The increasing use of SGLT2 inhibitors is one of the most important trends shaping the heart failure drugs market. These medicines, initially developed for diabetes treatment, are now widely adopted for heart failure management across HFrEF, HFpEF, and HFmrEF patient groups.

The broader application of SGLT2 inhibitors is expanding the treated patient population and increasing their revenue contribution. This trend is reducing dependence on traditional therapies such as beta blockers, ACE inhibitors, ARBs, and diuretics.

For instance, in May 2023, AstraZeneca received U.S. FDA approval for Farxiga to reduce cardiovascular death, hospitalization, and urgent heart failure visits among adults with heart failure regardless of left ventricular ejection fraction status.

Market Drivers

Rising Heart Failure Prevalence and Aging Population Driving Drug Demand

The increasing global burden of heart failure is the major factor supporting market expansion. Growing elderly populations, rising cases of diabetes, hypertension, obesity, and improved survival after cardiovascular events are increasing the number of patients requiring long-term treatment.

The rising adoption of guideline-directed medical therapies, including ARNI, SGLT2 inhibitors, MRAs, ACE inhibitors, ARBs, and beta blockers, is increasing prescription volumes for both branded and generic drugs.

According to healthcare estimates, around 6.7 million adults aged 20 years and above in the U.S. have heart failure, and the number is expected to increase significantly in the coming years, highlighting the growing treatment requirement.

Market Restraints

Limited Reimbursement and Access to Premium Heart Failure Therapies

Limited reimbursement coverage and affordability challenges may restrict market growth, especially in low- and middle-income countries.

Advanced therapies such as ARNI and SGLT2 inhibitors provide significant clinical benefits but often face accessibility issues due to high costs, limited insurance coverage, and insufficient specialist availability.

As a result, several emerging markets continue to depend on lower-cost generic cardiovascular medicines.

Market Opportunities

Expansion of HFpEF and HFmrEF Treatment Pool

Increasing focus on HFpEF and HFmrEF patient groups is creating significant growth opportunities.

Historically, these patient populations had limited treatment options; however, increasing adoption of SGLT2 inhibitors across different ejection fraction ranges is expanding treatment opportunities.

Improved diagnosis, wider guideline adoption, and increasing clinical research are expected to increase prescription volumes and create new revenue opportunities for market participants.

Market Challenges

Safety and Tolerability Concerns Associated with SGLT2 Inhibitors

Safety concerns related to SGLT2 inhibitors may challenge broader adoption, particularly among elderly, renal-impaired, and high-risk patients.

Potential risks such as diabetic ketoacidosis, volume depletion, and serious genitourinary infections require careful monitoring and patient selection.

These factors may slow adoption despite strong clinical benefits.

Segmentation Analysis

By Drug Class

ARNI Segment Dominates Due to Strong Treatment Value

Based on drug class, the market is segmented into:

• SGLT2 inhibitors
• ARNI
• Beta blockers
• ACE inhibitors & ARBs
• Mineralocorticoid receptor antagonists
• Diuretics
• Others

The ARNI segment dominated the market in 2025 due to the strong commercial performance of Entresto in chronic heart failure treatment.

High treatment value, strong clinical adoption, guideline recommendations, and recurring prescriptions supported segment leadership.

The SGLT2 inhibitors segment is expected to grow at a CAGR of 23.92% during 2026-2034, making it the fastest-growing drug class.

By Indication

HFrEF Segment Leads Due to Established Treatment Pathways

The HFrEF segment accounted for the largest market share in 2025 due to established treatment guidelines and extensive use of combination therapies.

The segment is expected to maintain approximately 57.6% share in 2026.

The HFpEF segment is projected to witness strong growth due to increasing availability of effective treatment options.

By Type

Branded Segment Holds Leading Market Position

The branded segment dominated the market in 2025 due to strong demand for high-value therapies such as Entresto, Farxiga, Jardiance, and other innovative treatments.

The segment is expected to hold approximately 68.1% share in 2026.

The generic segment is projected to grow at a CAGR of 12.47% during the forecast period due to increasing affordability and access.

By Route of Administration

Oral Segment Dominates Due to Long-Term Treatment Usage

The oral segment captured the largest share in 2025 due to widespread use of tablets and capsules for chronic heart failure management.

The segment is expected to hold approximately 93.9% share in 2026.

By Age Group

Adults Segment Dominates Due to Higher Disease Burden

The adults segment accounted for the largest market share in 2025 due to higher prevalence of heart failure among adult and elderly populations.

The segment is expected to maintain approximately 98.2% share in 2026.

By Distribution Channel

Retail Pharmacies and Drug Stores Lead Market

Retail pharmacies and drug stores dominated the market in 2025 due to recurring prescriptions and long-term outpatient treatment requirements.

The segment is expected to hold approximately 59.8% share in 2026.

Regional Insights

North America Heart Failure Drugs Market

North America dominated the global market in 2025 with a value of USD 5.11 billion.

Growth is supported by:

• Strong healthcare infrastructure
• High diagnosis rates
• Better reimbursement coverage
• Rapid adoption of branded therapies
• Increasing use of SGLT2 inhibitors and ARNI therapies

U.S. Heart Failure Drugs Market

The U.S. market is estimated to reach approximately USD 5.34 billion in 2026, representing around 39.8% of global market revenue.

Europe Heart Failure Drugs Market

Europe is projected to grow at a CAGR of 13.02% during 2026-2034.

Growth is supported by increasing adoption of guideline-based treatment, aging population, and rising use of SGLT2 inhibitors.

Germany Heart Failure Drugs Market

Germany is expected to reach approximately USD 0.76 billion in 2026.

U.K. Heart Failure Drugs Market

The U.K. market is expected to reach approximately USD 0.61 billion in 2026.

Asia Pacific Heart Failure Drugs Market

Asia Pacific is expected to be the fastest-growing region due to increasing cardiovascular disease burden, rising healthcare expenditure, and improving access to advanced therapies.

The regional market is projected to reach USD 2.75 billion in 2026.

China Heart Failure Drugs Market

China is expected to reach approximately USD 0.91 billion in 2026.

Japan Heart Failure Drugs Market

Japan is expected to reach approximately USD 0.61 billion in 2026.

India Heart Failure Drugs Market

India is expected to reach approximately USD 0.33 billion in 2026.

Latin America and Middle East & Africa

Latin America is projected to reach USD 0.74 billion in 2026, supported by increasing cardiovascular disease burden and improving access to medications.

The GCC market is expected to reach approximately USD 0.25 billion in 2026 due to healthcare modernization and chronic disease management initiatives.

Competitive Landscape

Key Industry Players

The global heart failure drugs market is moderately consolidated, with leading companies focusing on innovative therapies, clinical research, geographic expansion, and strategic collaborations.

Major companies include:

• Novartis AG
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Amgen Inc.
• Pfizer Inc.
• LEXICON Pharmaceuticals, Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz Inc.

Companies are strengthening their market positions through branded drug development, generic launches, lifecycle expansion, and clinical evidence generation.

Key Industry Developments

• January 2026: Viatris launched Inpefa/sotagliflozin in the UAE for heart failure treatment.
• October 2025: Sandoz Canada launched generic sacubitril-valsartan to expand ARNI treatment access.
• July 2025: Bayer received U.S. FDA approval for Kerendia in patients with heart failure and LVEF >=40%.
• January 2025: Lupin received FDA approval for generic sacubitril and valsartan tablets.
• August 2024: Bayer announced positive Phase III FINEARTS-HF trial results supporting future HF treatment expansion.

Report Coverage

The global heart failure drugs market report provides detailed analysis of market size, forecast, segmentation, regional performance, competitive landscape, product developments, regulatory environment, and emerging treatment trends.

The report evaluates key market drivers, restraints, opportunities, and challenges influencing market growth during the forecast period of 2026-2034.

Conclusion

The global heart failure drugs market is projected to grow from USD 11.79 billion in 2025 to USD 38.46 billion by 2034, driven by rising heart failure prevalence, aging populations, increasing adoption of guideline-directed medical therapies, and rapid expansion of SGLT2 inhibitors.

North America will continue to maintain market leadership due to advanced healthcare infrastructure, strong reimbursement systems, and high adoption of innovative therapies. Meanwhile, Asia Pacific is expected to witness significant growth due to increasing cardiovascular disease burden, improving healthcare access, and rising demand for advanced heart failure treatments.

Future market expansion will depend on continued innovation in cardiovascular therapies, improved affordability of premium drugs, wider adoption of personalized treatment approaches, and increased availability of advanced heart failure medicines across emerging economies.

Segmentation By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Region

By Drug Class

• SGLT2 Inhibitors
• ARNI
• Beta Blockers
• ACE Inhibitors & ARBs
• Mineralocorticoid Receptor Antagonists
• Diuretics
• Others

By Indication

• HFrEF
• HFpEF
• HFmrEF
• Acute Decompensated Heart Failure
• Post-MI Heart Failure / LV Dysfunction
• Others

By Type

• Branded
• Generics

By Route of Administration

• Oral
• Parenteral

By Age Group

• Adults
• Pediatrics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies
• Others

By Region

• North America (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Region
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• 4.3. New Product Launches, By Key Players
• 4.4. Pipeline Analysis, By Key Players
• 4.5. Regulatory & Reimbursement Scenario, By Key Countries/Region

5. Global Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. SGLT2 Inhibitors
  • 5.1.2. ARNI
  • 5.1.3. Beta Blockers
  • 5.1.4. ACE Inhibitors & ARBs
  • 5.1.5. Mineralocorticoid Receptor Antagonists
  • 5.1.6. Diuretics
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. HFrEF
  • 5.2.2. HFpEF
  • 5.2.3. HFmrEF
  • 5.2.4. Acute Decompensated Heart Failure
  • 5.2.5. Post-MI Heart Failure / LV Dysfunction
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Branded
  • 5.4.2. Generic
• 5.5. Market Analysis, Insights and Forecast - By Age Group
  • 5.5.1. Pediatrics
  • 5.5.2. Adults
• 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.6.1. Hospital Pharmacies
  • 5.6.2. Retail Pharmacies & Drug Stores
  • 5.6.3. Online Pharmacies
  • 5.6.4. Others
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. SGLT2 Inhibitors
  • 6.1.2. ARNI
  • 6.1.3. Beta Blockers
  • 6.1.4. ACE Inhibitors & ARBs
  • 6.1.5. Mineralocorticoid Receptor Antagonists
  • 6.1.6. Diuretics
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. HFrEF
  • 6.2.2. HFpEF
  • 6.2.3. HFmrEF
  • 6.2.4. Acute Decompensated Heart Failure
  • 6.2.5. Post-MI Heart Failure / LV Dysfunction
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Branded
  • 6.4.2. Generic
• 6.5. Market Analysis, Insights and Forecast - By Age Group
  • 6.5.1. Pediatrics
  • 6.5.2. Adults
• 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Retail Pharmacies & Drug Stores
  • 6.6.3. Online Pharmacies
  • 6.6.4. Others
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. SGLT2 Inhibitors
  • 7.1.2. ARNI
  • 7.1.3. Beta Blockers
  • 7.1.4. ACE Inhibitors & ARBs
  • 7.1.5. Mineralocorticoid Receptor Antagonists
  • 7.1.6. Diuretics
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. HFrEF
  • 7.2.2. HFpEF
  • 7.2.3. HFmrEF
  • 7.2.4. Acute Decompensated Heart Failure
  • 7.2.5. Post-MI Heart Failure / LV Dysfunction
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Branded
  • 7.4.2. Generic
• 7.5. Market Analysis, Insights and Forecast - By Age Group
  • 7.5.1. Pediatrics
  • 7.5.2. Adults
• 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Retail Pharmacies & Drug Stores
  • 7.6.3. Online Pharmacies
  • 7.6.4. Others
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. SGLT2 Inhibitors
  • 8.1.2. ARNI
  • 8.1.3. Beta Blockers
  • 8.1.4. ACE Inhibitors & ARBs
  • 8.1.5. Mineralocorticoid Receptor Antagonists
  • 8.1.6. Diuretics
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. HFrEF
  • 8.2.2. HFpEF
  • 8.2.3. HFmrEF
  • 8.2.4. Acute Decompensated Heart Failure
  • 8.2.5. Post-MI Heart Failure / LV Dysfunction
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Branded
  • 8.4.2. Generic
• 8.5. Market Analysis, Insights and Forecast - By Age Group
  • 8.5.1. Pediatrics
  • 8.5.2. Adults
• 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Retail Pharmacies & Drug Stores
  • 8.6.3. Online Pharmacies
  • 8.6.4. Others
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Australia
  • 8.7.5. Southeast Asia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. SGLT2 Inhibitors
  • 9.1.2. ARNI
  • 9.1.3. Beta Blockers
  • 9.1.4. ACE Inhibitors & ARBs
  • 9.1.5. Mineralocorticoid Receptor Antagonists
  • 9.1.6. Diuretics
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. HFrEF
  • 9.2.2. HFpEF
  • 9.2.3. HFmrEF
  • 9.2.4. Acute Decompensated Heart Failure
  • 9.2.5. Post-MI Heart Failure / LV Dysfunction
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Branded
  • 9.4.2. Generic
• 9.5. Market Analysis, Insights and Forecast - By Age Group
  • 9.5.1. Pediatrics
  • 9.5.2. Adults
• 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Retail Pharmacies & Drug Stores
  • 9.6.3. Online Pharmacies
  • 9.6.4. Others
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Heart Failure Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. SGLT2 Inhibitors
  • 10.1.2. ARNI
  • 10.1.3. Beta Blockers
  • 10.1.4. ACE Inhibitors & ARBs
  • 10.1.5. Mineralocorticoid Receptor Antagonists
  • 10.1.6. Diuretics
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Indication
  • 10.2.1. HFrEF
  • 10.2.2. HFpEF
  • 10.2.3. HFmrEF
  • 10.2.4. Acute Decompensated Heart Failure
  • 10.2.5. Post-MI Heart Failure / LV Dysfunction
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Branded
  • 10.4.2. Generic
• 10.5. Market Analysis, Insights and Forecast - By Age Group
  • 10.5.1. Pediatrics
  • 10.5.2. Adults
• 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Retail Pharmacies & Drug Stores
  • 10.6.3. Online Pharmacies
  • 10.6.4. Others
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Novartis AG
  • 11.2.2. AstraZeneca
  • 11.2.3. Boehringer Ingelheim International GmbH
  • 11.2.4. Merck & Co., Inc.
  • 11.2.5. Amgen Inc.
  • 11.2.6. Pfizer Inc.
  • 11.2.7. LEXICON PHARMACEUTICALS, INC.
  • 11.2.8. Viatris Inc.
  • 11.2.9. Teva Pharmaceutical Industries Ltd.
  • 11.2.10. Sandoz Inc.